Newsbenzinga
Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $200
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…